Skip to content

REGEN BIOPHARMA, INC.: 10-Q filed 2024-04-24

What REGEN BIOPHARMA, INC. reported in its quarterly report filed 2024-04-24 (fiscal Q2 2024): 25 published measures, 74 facts as tagged in accession 0001607062-24-000131.

This filing

Form
10-Q (quarterly report)
Filed
2024-04-24
Fiscal period
fiscal Q2 2024
Accession
0001607062-24-000131 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGEN BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-03-31140,770USD
At 2023-09-30353,617USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-03-315,316,734USD
At 2023-09-305,457,617USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-03-31-5,175,963USD
At 2023-12-31-5,241,463USD
At 2023-09-30-5,104,000USD
At 2023-03-31-4,929,755USD
At 2022-12-31-4,884,827USD
At 2022-09-30-8,036,059USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-122,473USD91
2023-10-01 to 2024-03-31-472,233USD183
2023-01-01 to 2023-03-31-54,978USD90
2022-10-01 to 2023-03-311,580,752USD182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-10-01 to 2024-03-31-371,657USD183
2022-10-01 to 2023-03-31-63,504USD182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2024-01-01 to 2024-03-3131,640USD91
2023-10-01 to 2024-03-3163,280USD183
2023-01-01 to 2023-03-3131,640USD90
2022-10-01 to 2023-03-3163,280USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-10-01 to 2024-03-31328,734USD183
2022-10-01 to 2023-03-31100,000USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-03-31-20,221,096USD
At 2023-09-30-19,748,863USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-01-01 to 2024-03-313,941,013shares91
2023-10-01 to 2024-03-313,831,431shares183
2023-01-01 to 2023-03-311,656,429shares90
2022-10-01 to 2023-03-313,364,578shares182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-101,071USD91
2023-10-01 to 2024-03-31-223,852USD183
2023-01-01 to 2023-03-31-78,842USD90
2022-10-01 to 2023-03-31-542,708USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-03-31123,037USD
At 2023-09-30131,037USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2024-01-01 to 2024-03-3117,063USD91
2023-10-01 to 2024-03-3134,828USD183
2023-01-01 to 2023-03-3112,085USD90
2022-10-01 to 2023-03-3129,444USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-03-315,173,049USD
At 2023-09-305,308,003USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-03-3129,798USD
At 2023-09-3029,674USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2024-03-3139,723USD
At 2023-09-300USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-01-01 to 2024-03-3140,133USD91
2023-10-01 to 2024-03-3187,661USD183
2023-01-01 to 2023-03-3136,446USD90
2022-10-01 to 2023-03-31131,959USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-03-314,114,622shares
At 2023-09-303,506,366shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-03-3178,114USD
At 2023-09-30121,037USD
At 2023-03-3187,700USD
At 2022-09-3051,204USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-03-3114,308,349USD
At 2023-09-3013,908,141USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2024-03-31-5,175,963USD
At 2023-09-30-5,104,000USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-122,473USD91
2023-10-01 to 2023-12-31-349,760USD92
2023-01-01 to 2023-03-31-54,978USD90
2022-10-01 to 2022-12-311,635,730USD92

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-122,473USD91
2023-10-01 to 2024-03-31-472,233USD183
2023-01-01 to 2023-03-31-54,978USD90
2022-10-01 to 2023-03-311,391,061USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-03-319,387USD91
2023-10-01 to 2024-03-3121,806USD183
2023-01-01 to 2023-03-3118,660USD90
2022-10-01 to 2023-03-3127,398USD182

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2023-10-01 to 2024-03-3139,723USD183
2022-10-01 to 2023-03-31-175,150USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2023-10-01 to 2024-03-31124USD183
2022-10-01 to 2023-03-315,248USD182

Inspect the source

Entity
REGEN BIOPHARMA, INC. / CIK 0001589150
Captured
2026-09-20T09:23:48.532Z
SEC response SHA-256
0bbe246b6080c7701ba978807745a4ba9de62971ab4db32e8d3e2fa2c4f26a87

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001589150.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))